Sanderling Ventures plans seventh fund

Sanderling Ventures hasn't raised a new fund since 2004, when the venture capital firm rounded up $421 million. Its seven-year silence on the that front--much longer than the typical four years between funds--led Forbes to declare the group one of the venture capital's walking dead. But PeHUB is reporting that Sanderling is back and looking to raise a seventh fund, though there's no word yet on how much the firm is aiming for.

A few of Sanderling's portfolio companies have paid dividends as of late. Alexion Pharmaceuticals paid $111 million to buy Taligen, which was 30 percent owned by Sanderling. Endocyte and Pacira both went public. The group has been busy on the investment front as well. PEHub notes that Sanderling invested in diagnostics company Lineagen in January, as well as Gemin X Pharmaceuticals and devicemaker InfraReDx last year.